help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shapiro, G.
Right arrow Articles by Evron, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shapiro, G.
Right arrow Articles by Evron, S.

Journal of Clinical Endocrinology & Metabolism, Vol 51, 429-432, Copyright © 1980 by Endocrine Society

ARTICLES

A novel use of spironolactone: treatment of hirsutism

G Shapiro and S Evron

An excess of androgens is the recognized cause of hirsutism in women. In this study, the antiandrogenic properties of spironolactone were tested clinically in 30 hirsute women. The drug was administered from the 4th to the 22nd day of each menstrual cycle. The moderate side effects in no case forced interruption of the treatment. Hair growth diminished substantially in 23 of the patients, the effect becoming evident 3-5 months after the commencement of treatment. Serum testosterone concentrations decreased in all patients, and estradiol increased in 25 women. Our data suggest that the antiandrogenic properties of spironolactone render it a suitable agent in the treatment of hirsutism.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
Endocrinology & Metabolism News, August 2005
J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 17a - 17a.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. Moghetti, R. Castello, N. Zamberlan, M. Rossini, D. Gatti, C. Negri, F. Tosi, M. Muggeo, and S. Adami
Spironolactone, But Not Flutamide, Administration Prevents Bone Loss in Hyperandrogenic Women Treated with Gonadotropin-Releasing Hormone Agonist
J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1250 - 1254.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Venturoli, O. Marescalchi, F. M. Colombo, S. Macrelli, B. Ravaioli, A. Bagnoli, R. Paradisi, and C. Flamigni
A Prospective Randomized Trial Comparing Low Dose Flutamide, Finasteride, Ketoconazole, and Cyproterone Acetate-Estrogen Regimens in the Treatment of Hirsutism
J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1304 - 1310.
[Abstract] [Full Text]

Home page
 Reproductive SciencesHome page
E. Diamanti-Kandarakis, G. Tolis, and A. J. Duleba
Androgens and Therapeutic Aspects of Antiandrogens in Women
Reproductive Sciences, July 1, 1995; 2(4): 577 - 592.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1980 by The Endocrine Society